Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03481738 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pyruvate Kinase Deficiency Global Longitudinal Registry

Study acronym: PEAK Registry
StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 76 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Site details revised at 13 of 52 sites
  2. 15 versions Re-verified since Jun 19, 2025, no change to tracked fieldsv61-v75
  3. Trial status: Recruiting to Active, Not Recruiting Study sites: 54 to 52 · Primary completion date: May 30, 2027 to May 31, 2027v60 Show 2 more changesShow less
    • Study sites: 54 to 52
    • Primary completion date: May 30, 2027 to May 31, 2027
  4. 4 versions Re-verified since Jan 23, 2025, no change to tracked fieldsv56-v59
  5. Site details revised at 1 of 54 sitesv55
Show 28 earlier versionsHide 28 earlier versions
  1. 18 versions Re-verified since Apr 28, 2023, no change to tracked fieldsv37-v54
  2. Site details revised at 1 of 54 sitesv36
  3. Re-verified, no change to tracked fieldsv35
  4. Study sites: 53 to 54v34
  5. 7 versions Re-verified since May 3, 2022, no change to tracked fieldsv27-v33
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is an observational (ie, noninterventional), longitudinal, multicenter, global registry for patients with pyruvate kinase (PK) deficiency, a rare nonspherocytic hemolytic anemia. This Registry will be open for enrollment for 7 years and all enrolled participants will be followed prospectively for a minimum of 2 years, and up to 9 years. Data will be collected from participating Registry Physicians, participants, and, where appropriate, parents/guardians who have provided informed consent or assent (where relevant) and authorization pursuant to applicable laws and regulations. Data should include demographic, clinical, and treatment data; and other data of relevance to the management of patients with PK deficiency. Annual chart review and data entry are expected in order to enhance longitudinal understanding of PK deficiency; however, no specific protocol schedule of assessment is required by this Registry protocol.
Trial Details
NCT Number NCT03481738
Lead Sponsor Agios Pharmaceuticals, Inc.
Conditions Pyruvate Kinase Deficiency
Enrollment 500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov